...
机译:P1.12-01二次/三线化疗后ES-SCLC患者的单臂多中心期II研究Apatinib
Medical Oncology Zhejiang Cancer Hospital;
Medical Oncology Zhejiang Cancer Hospital;
Medical Oncology He First Affiliated Hospital of Wenzhou Medical University;
Department of Respiratory the First Affiliated Hospital of Wenzhou Medical University;
Yinzhou People Hospital;
Medical Oncology Zhejiang Cancer Hospital;
Medical Oncology Zhejiang Cancer Hospital;
Radiation Oncology Zhejiang Cancer Hospital;
Medical Oncology Zhejiang Cancer Hospital;
Medical Oncology Zhejiang Cancer Hospital;
Medical Oncology Zhejiang Cancer Hospital;
Medical Oncology Zhejiang Cancer Hospital;
Medical Oncology Zhejiang Cancer Hospital;
Medical Oncology Zhejiang Cancer Hospital;
Medical Oncology Zhejiang Cancer Hospital;
Medical Oncology Zhejiang Cancer Hospital;
机译:P1.12-01二次/三线化疗后ES-SCLC患者的单臂多中心期II研究Apatinib
机译:吉非替尼的疗效和安全性在NSCLC患者中的第三线治疗激活初级吉替尼治疗的EGFR突变,然后进行二线化疗,单臂,前瞻性,多中心II研究(重新挑战,CTONG1304)
机译:Apatinib Plus Neoadjuvant化疗的作用随后在局部晚期胃腺癌患者中分离病理反应:单臂,开放标签,II期试验
机译:细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
机译:男性包皮环切术作为针对中国男性异性恋性传播疾病(STD)患者的生物医学HIV干预-可接受性研究和单臂概念测试试验。
机译:Apatinib患者在二线或第三线化疗后广泛的小细胞肺癌:II期单臂多环境前瞻性研究
机译:Apatinib患者在二线或第三线化疗后广泛的小细胞肺癌:II期,单臂,多环境,前瞻性研究